Base de dados : LILACS
Pesquisa : D12.776.124.486.485.114 [Categoria DeCS]
Referências encontradas : 995 [refinar]
Mostrando: 1 .. 10   no formato [Longo]

página 1 de 100 ir para página                         

  1 / 995 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Casanova, Cláudio
Texto completo
Id: biblio-841765
Autor: Aires, Juliana; Casanova, Claudio; Vernal, Sebastian; Nascimento, Margarida; Rodrigues, Sandra; Lerner, Ethan A; Roselino, Ana Maria.
Título: Maxadilan-simile expression in Nyssomyia neivai, a sandfly vector in an endemic region of Brazil, and its immunogenicity in patients with American tegumentary leishmaniasis
Fonte: Mem. Inst. Oswaldo Cruz;112(2):116-122, Feb. 2017. tab, graf.
Idioma: en.
Resumo: BACKGROUND Maxadilan (Max) is a salivary component in the sandfly Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral leishmaniasis. Max has a powerful vasodilatory effect and is a candidate vaccine that has been tested in experimental leishmaniasis. Nyssomyia neivai (Pinto 1926) is a vector of the pathogen responsible for American tegumentary leishmaniasis (ATL) in Brazil. OBJECTIVE We searched for Max expression in Ny. neivai and for antibodies against Max in ATL patients. METHODS cDNA and protein were extracted from the cephalic segment, including salivary glands, of Ny. neivai and analysed by polymerase chain reaction, DNA sequencing, and blotting assays. The results were compared with data obtained from Lu. longipalpis samples. We quantified antibodies against Max in serum samples from 41 patients with ATL (31 and 10 with the cutaneous and mucocutaneous forms, respectively) and 63 controls from the endemic northeastern region of São Paulo state, using enzyme-linked immunosorbent assay. FINDINGS Recognition of a Max-simile peptide by specific antibodies confirmed expression of a Max sequence in Ny. neivai (GenBank EF601123.1). Compared to controls, patients with ATL presented higher levels of antibodies against Max (p = 0.004); 24.4% of the patients with ATL and 3.2% of the controls presented anti-Max levels above the cutoff index (p = 0.014). The anti-Max levels were not associated with the specific clinical form of ATL, leishmanin skin test response, absence or presence of amastigotes in histopathologic exam, results of indirect immunofluorescence testing for leishmaniasis, or duration of cutaneous form disease. MAIN CONCLUSION High serum anti-Max levels did not protect patients against ATL, but confirmed previous natural exposure to Ny. neivai bites in this ATL endemic region.
Responsável: BR1.1 - BIREME


  2 / 995 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-841749
Autor: Silva, Kleverton Ribeiro da; Mendonça, Vitor Rosa Ramos de; Silva, Kellen Matuzzy; Nascimento, Leopoldo Fabrício Marçal do; Mendes-Sousa, Antonio Ferreira; Pinho, Flaviane Alves de; Barral-Netto, Manoel; Barral, Aldina Maria Prado; Cruz, Maria do Socorro Pires e.
Título: Scoring clinical signs can help diagnose canine visceral leishmaniasis in a highly endemic area in Brazil
Fonte: Mem. Inst. Oswaldo Cruz;112(1):53-63, Jan. 2017. tab, graf.
Idioma: en.
Resumo: Canine visceral leishmaniasis (CVL) diagnosis is still a challenge in endemic areas with limited diagnostic resources. This study proposes a score with the potential to distinguish positive CVL cases from negative ones. We studied 265 dogs that tested positive for CVL on ELISA and parasitological tests. A score ranging between 0 and 19 was recorded on the basis of clinical signs. Dogs with CVL had an overall higher positivity of the majority of clinical signs than did dogs without CVL or with ehrlichiosis. Clinical signs such as enlarged lymph nodes (83.93%), muzzle/ear lesions (55.36%), nutritional status (51.79%), bristle condition (57.14%), pale mucosal colour (48.21%), onychogryphosis (58.93%), skin lesion (39.28%), bleeding (12.50%), muzzle depigmentation (41.07%), alopecia (39.29%), blepharitis (21.43%), and keratoconjunctivitis (42.86%) were more frequent in dogs with CVL than in dogs with ehrlichiosis or without CVL. Moreover, the clinical score increased according to the positivity of all diagnostic tests (ELISA, p < 0.001; parasite culture, p = 0.0021; and smear, p = 0.0003). Onychogryphosis (long nails) [odds ratio (OR): 3.529; 95% confidence interval (CI): 1.832-6.796; p < 0.001], muzzle depigmentation (OR: 4.651; 95% CI: 2.218-9.750; p < 0.001), and keratoconjunctivitis (OR: 5.400; 95% CI: 2.549-11.441; p < 0.001) were highly associated with CVL. Interestingly, a score cut-off value ≥ 6 had an area under the curve of 0.717 (p < 0.0001), sensitivity of 60.71%, and specificity of 73.64% for CVL diagnosis. The clinical sign-based score for CVL diagnosis suggested herein can help veterinarians reliably identify dogs with CVL in endemic areas with limited diagnostic resources.
Responsável: BR1.1 - BIREME


  3 / 995 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-974431
Autor: Santos, Mariana Lopes dos; Quintilio, Wagner; Manieri, Tania Maria; Tsuruta, Lilian Rumi; Moro, Ana Maria.
Título: Advances and challenges in therapeutic monoclonal antibodies drug development
Fonte: Braz. J. Pharm. Sci. (Online);54(spe):e01007, 2018. graf, ilus.
Idioma: en.
Resumo: The use of serum containing polyclonal antibodies from animals immunized with toxins marked the beginning of the application of antibody-based therapy in late nineteenth century. Advances in basic research led to the development of the hybridoma technology in 1975. Eleven years later, the first therapeutic monoclonal antibody (mAb) was approved, and since then, driven by technological advances, the development of mAbs has played a prominent role in the pharmaceutical industry. In this review, we present the developments to circumvent problems of safety and efficacy arising from the murine origin of the first mAbs and generate structures more similar to human antibodies. As of October 2017, there are 61 mAbs and 11 Fc-fusion proteins in clinical use. An overview of all mAbs currently approved is provided, showing the development of sophisticated mAbs formats that were engineered based on the challenges posed by therapeutic indications, including antibody-drug conjugates (ADC) and glycoengineered mAbs. In the field of immunotherapy, the use of immunomodulators, bispecific mAbs and CAR-T cells are highlighted. As an example of promising therapy to treat infectious diseases, we discuss the generation of neutralizing monoclonal-oligoclonal antibodies obtained from human B cells. Scientific and technological advances represent mAbs successful translation to the clinic
Responsável: BR1.1 - BIREME


  4 / 995 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-964587
Autor: Castro, Jacqueline Ribeiro de; Souza, Mariana Assunção de; Cardoso Neto, Antônio Bertolino; Moreira, Rafael Quirino; Salaberry, Sandra Renata Sampaio; Guimarães, Ednaldo Carvalho; Lima, Anna Monteiro Correia.
Título: Presence of antibodies against Leptospira spp. in dogs of Uberlandia, MG, Brazil / Presença de anticorpos contra Leptospira spp. em cães no município de Uberlândia, MG, Brasil
Fonte: Biosci. j. (Online);31(4):1183-1188, july/aug. 2015.
Idioma: en.
Resumo: The aim of this study was to investigate the occurrence of antibodies against Leptospira spp. and risk factors related to the epidemiology of leptospirosis in dogs living in the urban area of the municipality of Uberlandia, Minas Gerais, Brazil. Blood serum samples were examined from 268 dogs from the municipality's North, South, East, West and Central sanitary districts. The samples were collected during an animal vaccination campaign against rabies in August 2008. The occurrence of antibodies against specific leptospiral serovars was determined by the microscopic agglutination test (MAT). Multivariable logistic regression was used to evaluate the association between sex, age, previous vaccination, habitation, presence of rats, and history of human and/or animal leptospirosis on the occurrence of infection. The occurrence of canine leptospirosis was 28.36% (76/268), the most prevalent serovars were: Autumnalis (34.21%), Tarassovi (23.58%), Canicola (17.11%) and Grippotyphosa (14.47%). No risk factors were found to be statistically significant (p> 0,05 for all examined variables). The fact that close to 30% of dogs showed evidence of past infection with Leptospira points to the need for the adoption of preventive measures, as the disease may represent a public health risk.

O objetivo deste estudo foi investigar a ocorrência de anticorpos contra Leptospira spp. e os fatores de risco relacionados à epidemiologia da leptospirose em cães que vivem na área urbana do município de Uberlândia, Minas Gerais, Brasil. Amostras de soro foram examinados a partir de 268 cães dos distritos sanitários Norte, Sul, Leste, Oeste e Central. As amostras foram colhidas durante a campanha de vacinação contra a raiva animal em agosto de 2008. A ocorrência de anticorpos contra sorovares específicos foi determinada pelo teste de Soroaglutinação Microscópica (SAM). Foi utilizada a regressão logística multivariada para avaliar a associação entre sexo, idade, a vacinação, habitação, presença de ratos e história de humanos e/ou leptospirose animal na ocorrência da infecção. A ocorrência da leptospirose canina foi de 28,36% (76/268), os sorovares mais prevalentes foram: Autumnalis (34,21%), Tarassovi (23,58%), Canicola (17,11%) e Grippotyphosa (14,47%). Quanto aos fatores de risco analisados, não foi encontrada diferença estatística significativa (p> 0,05 para todas as variáveis analisadas). O fato de 30% dos cães terem apresentado evidência de infecção causada por Leptospira aponta para a necessidade da adoção de medidas preventivas, pois a doença pode representar um risco para a saúde pública.
Responsável: BR396.1 - Biblioteca Central


  5 / 995 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Cuba
Texto completo
Texto completo
Id: biblio-960435
Autor: Fernández Águila, Julio D; García Vega, Yanelda de los Ángeles; Hernández Casaña, Patricia; Hernández Cruz, Calixto; Medina Rodríguez, Bárbaro Andrés; Viada González, Carmen Elena.
Título: Seguridad y efecto del uso compasivo del anticuerpo monoclonal anti-CD20 CIMABior® / Safety and response to treatment of compassionate use of an anti-CD20 monoclonal antibody CIMABior®
Fonte: Rev. cuba. hematol. inmunol. hemoter;33(4):35-49, oct.-dic. 2017. tab.
Idioma: es.
Resumo: Introducción: el uso de anticuerpos monoclonales transformó el tratamiento de los linfomas no hodgkinianos. El Centro de Inmunología Molecular generó un anticuerpo anti-CD20 (CIMABior®) biosimilar del rituximab, que se ha caracterizado desde el punto de vista biológico, pero la seguridad y eficacia aún están en estudio. Objetivo: evaluar la seguridad y la respuesta al tratamiento con CIMABior ®, en pacientes con síndromes linfoproliferativos de células B tratados con intención compasiva. Métodos: estudio multicéntrico, exploratorio, con dos grupos de tratamiento (monoterapia o combinado con quimioterapia) no controlado, ni aleatorizado. Se incluyeron adultos con linfomas no hodgkinianos y leucemia linfocítica crónica, no elegibles para el ensayo clínico en ejecución con este producto. Se determinó la frecuencia de eventos adversos y se caracterizaron. La respuesta al tratamiento se definió como: remisión completa, remisión parcial, enfermedad estable o en progresión. Se calculó la tasa de respuesta objetiva (remisión completa más remisión parcial) con el intervalo de confianza al 95 por ciento, se evaluó la relación de algunas variables con la respuesta y se estimó la razón de Odss. Como medida de balance beneficio-riesgo se estimó el factor de Bayes. Resultados: los eventos adversos más frecuentes fueron: temblor (12,8 por ciento) y fiebre (10,3 por ciento). Los relacionados con el producto (43,4 por ciento) fueron leves o moderados y evolucionaron hacia la recuperación. No se informó muerte asociada directamente al tratamiento. Se constató respuesta objetiva global de 71,2 por ciento (59,6 por ciento de remisiones completas y 11,5 por ciento, parciales). La respuesta objetiva en el grupo de monoterapia fue de 66,7 por ciento y de 73,0 por ciento en el grupo de CIMABior® más quimioterapia, con remisiones completas de 46,7 por ciento y 64,9 por ciento, respectivamente. Conclusiones: el AcM CIMABior® es seguro, bien tolerado y se demostraron evidencias de efecto. El tratamiento aportó un beneficio clínico superior al riesgo de desarrollar algún evento adverso grave(AU)

Introduction : The use of monoclonal antibodies transformed the treatment of non-Hodgkin lymphomas. The Center of Molecular Immunology created an anti-CD20 monoclonal antibody (CIMABior®), biosimilar of rituximab, which has been characterized from a biological point of view, but the safety and effectiveness are still being studied. Objective: Evaluate the safety and response to treatment, in patients with B-cell malignancies with compassionate use of CIMABior®. Methods : A multicenter, exploratory, non-controlled, non-randomized study was conducted with two variants of treatments (monotherapy or combined with chemotherapy). Adults with non-Hodgkin lymphomas and chronic lymphocytic leukemia not eligible for clinical trial with this product were included. Frequency of adverse events was calculated and those were characterized. The response to treatment was defined as: complete response, partial response, stable disease or progressive disease. Overall response rate (complete plus partial remission) was calculated with 95 percent confidence interval. The relation of some variables with response was estimated per Odss ratio. As a measure of the benefit-risk balance, the Bayes factor was estimated. Results : The more frequent adverse events were: tremors (12.8 percent) and fever (10.3 percent). Those related to the product (43.4 percent) were minor and evolved to recovery. There were no deaths in reference to the treatment. An overall response of 71.2 percent was confirmed (59.6 percent complete remissions and 11.5 percent partial remission). The monotherapy group objective response was 66.7 percent and 73.0 percent in the CIMABior® plus chemotherapy group, with complete remissions of 46.7 percent and 64.9 percent respectively. Conclusions: The monoclonal antibodies CIMABor® is safe, well tolerated and evidences of its effectiveness was demonstrated. The treatment provided a superior clinical benefit to the risk of developing a severe adverse event(AU)
Responsável: CU1.1 - Biblioteca Médica Nacional


  6 / 995 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-985511
Autor: Macchia de Sánchez, Carla Lorena; Sánchez-Flórez, Javier Augusto.
Título: Prevalence of thyroid autoimmunity in a population of pregnant women in Santa Marta, Magdalena (Colombia) / Prevalencia de autoinmunidad tiroidea en una población de gestantes de Santa Marta, Magdalena (Colombia)
Fonte: Rev. colomb. obstet. ginecol;69(4):260-269, Oct.-Dec. 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective: To describe the prevalence of thyroid autoimmunity in a hospital-based population of pregnant women, and to explore its frequency in euthyroid and hypothyroid women, as well as the association between autoimmunity and the presence of obstetric complications. Materials and methods: Descriptive cross-sectional study. Accesible population: pregnant women seen at Centros Hospitalarios del Caribe (CEHOCA) in the city of Santa Marta, Magdalena (Colombia), between August 1 and October 31, 2017. Convenience sampling. Sample size: 120 subjects. Thyroid stimulating hormone (TSH), free thyroxine (T4), free triiodothyronine (T3), thyroglobulin (TG) and thyroid peroxidase (TPO) antibodies were determined. Descriptive statistics were used. Prevalence was calculated as the number of women with positive TG or TPO antibodies/number of women surveyed. Categorization by type of positive antibody and thyroid function (normal or hypothyroidism) was also done. Results: In women with uncomplicated pregnancies, the frequency of thyroid autoimmunity was 14.29%. Five patients (4.5%) had positive TPO antibodies, 14 patients (12.61%) had positive TG antibodies, while 3 of the women were positive for the two types of antibodies. Antithyroglobulin antibodies were the most frequent. Autoimmunity was found in 13.5% of euthyroid women, and in 18.2% of the women with subclinical hypothyroidism. No association was found between the presence of antibodies and miscarriage, pregnancy-associated hypertension or preterm delivery. Conclusions: The presence of antithyroid antibodies was found in 1 out of every 7 pregnant women as a sign of autoimmunity. Further observations are required in order to determine frequencies and normality ranges in the local population, as well as the clinical significance of this thyroid autoimmunity.

RESUMEN Objetivo: describir la prevalencia de autoinmunidad tiroidea en una población de gestantes de base hospitalaria, y hacer una exploración a la frecuencia en pacientes eutiroideas o hipotiroideas, y de la asociación entre autoinmunidad y la presencia de complicaciones obstétricas. Materiales y métodos: estudio de corte transversal, descriptivo. Población accesible: gestantes atendidas en Centros Hospitalarios del Caribe (CEHOCA), de la ciudad de Santa Marta, Magdalena (Colombia), entre el 1 de agosto y el 31 de octubre de 2017. Muestreo por conveniencia. Tamaño muestral: 120 sujetos. Se determinó hormona tiroestimulante (TSH), T4 libre, T3 libre, anticuerpos antitiroglobulina (ATG) y antiperoxidasa (ATPO). Se utilizó estadística descriptiva. La prevalencia se calculó como número de mujeres con anticuerpos ATG o ATPO positivos/número de mujeres encuestadas, además se categorizó por tipo de anticuerpo positivo y función tiroidea (normal o hipotiroidismo). Resultados: en las gestantes con embarazo sin mención de complicación la frecuencia de autoinmunidad tiroidea fue del 14,29 %. Cinco pacientes (4,5 %) presentaron anticuerpos ATPO positivos, 14 pacientes (12,61 %) anticuerpos ATG positivos, en tanto que 3 embarazadas mostraron positividad para ambos tipos de anticuerpos. Los anticuerpos antitiroglobulina fueron los más frecuentes. Se halló autoinmunidad en el 13,5 % de las gestantes eutiroideas, y en el 18,2 % de las pacientes con hipotiroidismo subclínico. No se encontró asociación entre la presencia de anticuerpos y la presencia de aborto, hipertensión asociada al embarazo o parto pretérmino. Conclusiones: una de cada 7 gestantes mostró presencia de anticuerpos antitiroideos como signo de autoinmunidad. Son necesarias más observaciones a fin de poder establecer frecuencias y rangos de normalidad en la población local y el significado clínico de esta autoinmunidad tiroidea.
Responsável: CO76


  7 / 995 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1009886
Autor: Barbieri, Elena S; Rodríguez, Daniela V; Marin, Raúl E; Setti, Walter; Romero, Sandra; Barrandeguy, María; Parreño, Viviana.
Título: Relevamiento serológico de anticuerpos contra enfermedades virales de interés sanitario en llamas (Lama glama) de la provincia de Jujuy, Argentina / Serological survey of antibodies aainst vital diseases of public health interest in llamas (Lama glama) from Jujuy rpovince, Argentina
Fonte: Rev. argent. microbiol;46(1):53-57, mar. 2014.
Idioma: es.
Resumo: Las poblaciones de llamas de Argentina se concentran principalmente en la provincia de Jujuy; su explotación representa un importante recurso económico de las comunidades altoandinas. El objetivo de este trabajo fue evaluar la seroprevalencia de anticuerpos contra algunos agentes virales asociados a enfermedades de impacto productivo en rodeos de llamas de Jujuy. Se analizaron 349 sueros de llamas adultas de 6 departamentos de la puna jujeña ubicados por encima de los 3300 msnm. Se obtuvo una prevalencia del 100 % para rotavirus grupo A y del 70 % para el virus parainfluenza-3 bovino, mientras que no se detectaron reactores para herpesvirus bovino 1, virus de la diarrea viral bovina, influenza A humana (H1N1) e influenza equina (H3N8). Los resultados obtenidos confirman la amplia distribución de rotavirus y virus parainfluenza y la baja susceptibilidad a herpesvirus y pestivirus en las tropas de llamas de la puna jujeña

Llama population from Argentina is mainly concentrated in the Andean Puna, Jujuy. Llamas represent an important economic resource for the Andean communities. The aim of this study was to investigate the prevalence of antibodies against viral antigens associated to viral diseases of economic impact (neonatal diarrhea, reproductive and respiratory syndromes). A total of 349 serum samples from adult llamas were analyzed. The obtained antibody prevalence was 100 % for Rotavirus A and 70 % for Bovine parainfluenza virus 3. In contrast, no reactors were detected to Bovine herpesvirus 1, Bovine viral diarrhea virus 1, Human influenza A virus (H1N1) and Equine influenza virus (H3N8). These results confirm the wide circulation of rotavirus and parainfluenza virus in Argentinean llamas and suggest that susceptibility to infection with bovine herpesvirus, pestivirus and influenza A viruses is low. This serologic survey provides novel information regarding the epidemiology of viral diseases affecting llamas from the Argentinean Andean Puna
Responsável: AR635.1 - FCVyS - Servicio de Información y Documentación


  8 / 995 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-681968
Autor: Silva, Silvia Fernandes Ribeiro da; Ferreira, Glaucia Maria; Silva, Sonia Leite da; Alves, T ania Maria de Oliveira; Ribeiro, Ilana Farias; Ribeiro, Thyciana Rodrigues; Cavalcante, Maria do Carmo Serpa.
Título: Red blood cell and leukocyte alloimmunization in patients awaiting kidney transplantation
Fonte: Rev. bras. hematol. hemoter;35(3):185-188, jun. 2013. tab.
Idioma: en.
Resumo: Objective: To determine the rates of red blood cell and leukocyte alloimmunization in patients with chronic kidney disease awaiting kidney transplantation. Methods: In this cross-sectional and prospective study, the serum of 393 chronic kidney disease patients on a transplant waiting list in Ceará, Northeastern Brazil were tested for red cell and leukocyte antibodies. In addition, demographic, clinical and laboratory data were collected. Results: The average age in the sample of 393 patients was 34.1 ± 14 years. Slightly more than half (208; 52.9%) were male. The average numbers of transfusions and gestations were 3.1 ± 3.3 and 1.6 ± 6, respectively. One third (33.6%) were alloimmunized: 78% with leukocyte antibodies, 9.1% with red cell antibodies and 12.9% with both. Red cell antibodies were detected in 29 cases (7.4%), 17 of whom were women, who had received more transfusions than the males (p-value < 0.0001). The most frequently detected red cell antibodies belonged to the Rh (24.1%) and Kell (13.8%) blood group systems. Leukocyte antibodies were detected in 30.5% of cases, 83 of whom were women, who had received more transfusions than the males (p-value < 0.0001) and were more reactive to panel reactive antibodies (p-value < 0.0001). The mean alloreactivity to panel reactive antibodies was 47.7 ± 31.2%. Conclusion: Chronic kidney disease patients on the transplant waiting list in Ceará, Brazil, display high ...
Responsável: BR408.1 - Biblioteca da Faculdade de Medicina - BFM


  9 / 995 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Colli, W
Texto completo
Id: lil-623582
Autor: Zingales, B; Arruda, M. V; Colli, W.
Título: Carbohydrate epitopes (GALF - MANP) recognized by antibodies that inhibit trypamastigote interization into mammalian cells
Fonte: Mem. Inst. Oswaldo Cruz;83(supl.1):240-242, Nov. 1988.
Idioma: en.
Conferência: Apresentado em: Annual Meeting on Basic Research in Chagas's disease, 15, Apresentado em: Meeting of the Brazilian Society of Protozoology4, Caxambu, 7-10 Nov. 1988.
Responsável: BR1.1 - BIREME


  10 / 995 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1003291
Autor: Arietti, Alba Soledad; Pedano, Valeria Cristina; Neme, Viviana; Racca, Agustina; Sotelo, Vanessa; Rozzatti, Maria Soledad; Gobbi, Carla; Vigliano, Mercedes; Alba, Paula; Demarchi, Marcela.
Título: Niveles de anticuerpos anti-anexina A5 y manifestaciones de síndrome antifosfolípido primario obstétrico / Levels of anti-anexinal antibodies A5 and manifestations of obstetric primary antiphospholipid syndrome
Fonte: Rev. argent. reumatol;29(4):6-12, dic. 2018. ilus, tab.
Idioma: es.
Resumo: El Síndrome Antifosfolípidos (SAF) describe un trastorno trombofílico autoinmune caracterizado por complicaciones obstétricas. La Anexina A5 (Anx A5) es una proteína que se estudia como un nuevo autoantígeno presente en el SAF, la presencia de autoanticuerpos frente a Anx A5 podría causar trombosis placentaria y pérdida del embarazo. El objetivo de este estudio fue analizar los niveles de IgG e IgM anti-Anx A5 en mujeres con SAF primario obstétrico y su asociación con diferentes complicaciones en una población de la ciudad de Córdoba. Se trabajó con muestras de pacientes puérperas que asistieron al Hospital Córdoba y al Hospital Materno Neonatal durante los años 2013-2017 con diagnóstico de SAF obstétrico y un grupo control formado por pacientes con embarazos normales. En la mayoría de las pacientes estudiadas, los niveles de IgG e IgM anti-Anx A5 se encontraron por debajo del rango de referencia, se mostró un aumento estadísticamente significativo de los niveles de IgG en pacientes con SAF respecto al grupo control. Pero no existieron asociaciones específicas entre los niveles de anticuerpo y los tres tipos de manifestaciones clínicas presentes en los criterios de clasificación. Estos hallazgos podrían sugerir una relación entre los anticuerpos anti-Anx A5 con el SAF obstétrico.

Antiphospholipid Syndrome (APS) describes an autoimmune thrombophilic disorder characterized by obstetric complications. Annexin A5 (Anx A5) is a protein that is studied as a new autoantigen present in APS, the presence of autoantibodies against Anx A5 could cause placental thrombosis and possibly pregnancy loss. The aim of this study was to analyze levels of IgG and IgM anti-Anx A5 in women with primary obstetric APS and its association with different complications in a population of the city of Córdoba. We worked with samples of puerperal patients who attended the Córdoba Hospital and the Maternal Neonatal Hospital during the years 2013-2017 with a diagnosis of obstetric APS and a control group formed by patients with normal pregnancies. In most of the patients studied, levels of IgG and IgM anti-Anx A5 were below the reference range, is demonstrate an increase statistically significant in the levels of the IgG in patients with APS compared with control group. But there were no specific associations between antibody levels and the three types of obstetric clinical manifestations present in the classification criteria. These findings could suggest a relationship between anti-Anx A5 antibodies and obstetric APS.
Responsável: AR423.1 - Biblioteca



página 1 de 100 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde